367 related articles for article (PubMed ID: 33576905)
41. Signaling Pathways of Purinergic Receptors and Their Interactions with Cholinergic and Adrenergic Pathways in the Lacrimal Gland.
Hodges RR; Dartt DA
J Ocul Pharmacol Ther; 2016 Oct; 32(8):490-497. PubMed ID: 27463365
[TBL] [Abstract][Full Text] [Related]
42. Purinergic signaling during macrophage differentiation results in M2 alternative activated macrophages.
Barberà-Cremades M; Baroja-Mazo A; Pelegrín P
J Leukoc Biol; 2016 Feb; 99(2):289-99. PubMed ID: 26382298
[TBL] [Abstract][Full Text] [Related]
43. Potentiation of temozolomide antitumor effect by purine receptor ligands able to restrain the in vitro growth of human glioblastoma stem cells.
D'Alimonte I; Nargi E; Zuccarini M; Lanuti P; Di Iorio P; Giuliani P; Ricci-Vitiani L; Pallini R; Caciagli F; Ciccarelli R
Purinergic Signal; 2015 Sep; 11(3):331-46. PubMed ID: 25976165
[TBL] [Abstract][Full Text] [Related]
44. Purinergic signaling in scarring.
Ferrari D; Gambari R; Idzko M; Müller T; Albanesi C; Pastore S; La Manna G; Robson SC; Cronstein B
FASEB J; 2016 Jan; 30(1):3-12. PubMed ID: 26333425
[TBL] [Abstract][Full Text] [Related]
45. Involvement of purinergic system in the release of cytokines by macrophages exposed to glioma-conditioned medium.
Bergamin LS; Braganhol E; Figueiró F; Casali EA; Zanin RF; Sévigny J; Battastini AM
J Cell Biochem; 2015 May; 116(5):721-9. PubMed ID: 25546398
[TBL] [Abstract][Full Text] [Related]
46. P19 embryonal carcinoma cells as in vitro model for studying purinergic receptor expression and modulation of N-methyl-D-aspartate-glutamate and acetylcholine receptors during neuronal differentiation.
Resende RR; Majumder P; Gomes KN; Britto LR; Ulrich H
Neuroscience; 2007 May; 146(3):1169-81. PubMed ID: 17418494
[TBL] [Abstract][Full Text] [Related]
47. Ribose modified nucleosides and nucleotides as ligands for purine receptors.
Jacobson KA; Ravi RG; Nandanan E; Kim HS; Moro S; Kim YC; Lee K; Barak D; Marquez VE; Ji XD
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):333-41. PubMed ID: 11563046
[TBL] [Abstract][Full Text] [Related]
48. Purinergic receptors are part of a functional signaling system for proliferation and differentiation of human epidermal keratinocytes.
Greig AV; Linge C; Terenghi G; McGrouther DA; Burnstock G
J Invest Dermatol; 2003 Jun; 120(6):1007-15. PubMed ID: 12787128
[TBL] [Abstract][Full Text] [Related]
49. Alteration of purinergic signaling in diabetes: Focus on vascular function.
Zhou R; Dang X; Sprague RS; Mustafa SJ; Zhou Z
J Mol Cell Cardiol; 2020 Mar; 140():1-9. PubMed ID: 32057736
[TBL] [Abstract][Full Text] [Related]
50. Purinergic Signaling in Controlling Macrophage and T Cell Functions During Atherosclerosis Development.
Ferrari D; la Sala A; Milani D; Celeghini C; Casciano F
Front Immunol; 2020; 11():617804. PubMed ID: 33664731
[TBL] [Abstract][Full Text] [Related]
51. Conversion of extracellular ATP into adenosine: a master switch in renal health and disease.
Dwyer KM; Kishore BK; Robson SC
Nat Rev Nephrol; 2020 Sep; 16(9):509-524. PubMed ID: 32641760
[TBL] [Abstract][Full Text] [Related]
52. Emerging roles of purinergic signaling in anti-cancer therapy resistance.
Zanoni M; Pegoraro A; Adinolfi E; De Marchi E
Front Cell Dev Biol; 2022; 10():1006384. PubMed ID: 36200041
[TBL] [Abstract][Full Text] [Related]
53. Current state of purinoceptor research.
Burnstock G
Pharm Acta Helv; 1995 Mar; 69(4):231-42. PubMed ID: 7651967
[TBL] [Abstract][Full Text] [Related]
54. Specific Activation of A3, A2A and A1 Adenosine Receptors in CD73-Knockout Mice Affects B16F10 Melanoma Growth, Neovascularization, Angiogenesis and Macrophage Infiltration.
Koszałka P; Gołuńska M; Urban A; Stasiłojć G; Stanisławowski M; Majewski M; Składanowski AC; Bigda J
PLoS One; 2016; 11(3):e0151420. PubMed ID: 26964090
[TBL] [Abstract][Full Text] [Related]
55. The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.
Antonioli L; Blandizzi C; Pacher P; Haskó G
Pharmacol Rev; 2019 Jul; 71(3):345-382. PubMed ID: 31235653
[TBL] [Abstract][Full Text] [Related]
56. Adenosine and ATP receptors.
Sawynok J
Handb Exp Pharmacol; 2007; (177):309-28. PubMed ID: 17087128
[TBL] [Abstract][Full Text] [Related]
57. P2Y1 and P2Y13 purinergic receptors mediate Ca2+ signaling and proliferative responses in pulmonary artery vasa vasorum endothelial cells.
Lyubchenko T; Woodward H; Veo KD; Burns N; Nijmeh H; Liubchenko GA; Stenmark KR; Gerasimovskaya EV
Am J Physiol Cell Physiol; 2011 Feb; 300(2):C266-75. PubMed ID: 20962269
[TBL] [Abstract][Full Text] [Related]
58. Exploration of therapeutic applicability and different signaling mechanism of various phytopharmacological agents for treatment of breast cancer.
Singh V; Kumar K; Purohit D; Verma R; Pandey P; Bhatia S; Malik V; Mittal V; Rahman MH; Albadrani GM; Arafah MW; El-Demerdash FM; Akhtar MF; Saleem A; Kamel M; Najda A; Abdel-Daim MM; Kaushik D
Biomed Pharmacother; 2021 Jul; 139():111584. PubMed ID: 34243623
[TBL] [Abstract][Full Text] [Related]
59. Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy.
de Leve S; Wirsdörfer F; Jendrossek V
Front Immunol; 2019; 10():698. PubMed ID: 31024543
[TBL] [Abstract][Full Text] [Related]
60. Purinergic receptors in airway epithelia.
Lazarowski ER; Boucher RC
Curr Opin Pharmacol; 2009 Jun; 9(3):262-7. PubMed ID: 19285919
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
